EUVIMEDObjevte EUVIMED
Crossref

Construction of a Cuproptosis-Associated Long Noncoding RNA Prognostic Signature and Immune Profiling in Gastric Cancer

Feng Zhao, Jialing Xu, Wei Li, Zhe Wang

Journal of Visualized Experiments · 2026-11-10 · (237)

DOI: 10.3791/71266 ↗

At a glance

Journal article in Journal of Visualized Experiments, published online on 2026-11-10. Written by Feng Zhao and 3 co-authors.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

This study constructed and internally evaluated a cuproptosis-associated long noncoding RNA (lncRNA) prognostic signature in gastric cancer by integrating public transcriptomic and clinical data with survival modeling, immune-feature analysis, mutation profiling, in silico pharmacogenomic prediction, and preliminary tissue-level validation. Statistical co-expression was interpreted as an association rather than evidence of direct functional regulation of cuproptosis. The analysis began with the acquisition of The Cancer Genome Atlas Stomach Adenocarcinoma (TCGA-STAD) transcriptome and clinical data, harmonization, lncRNA annotation, quality control, and a predefined 1:1 training/testing split. Cuproptosis-associated lncRNAs were operationally screened by Pearson co-expression with a 19-gene cuproptosis panel, followed by univariate Cox analysis, 10-fold least absolute shrinkage and selection operator (LASSO)-Cox variable selection, multivariable Cox model fitting, fixed-cutoff risk stratification, Kaplan-Meier analysis, time-dependent receiver operating characteristics (ROC) analysis, and nomogram construction. Downstream analyses assessed functional enrichment, single-sample gene set enrichment analysis (ssGSEA)-derived immune functions, somatic mutation patterns, tumor mutational burden, legacy Tracking of Indels by Decomposition (TIDE) output, and transcriptome-predicted drug sensitivity. Quantitative reverse-transcription PCR (qRT-PCR) in 16 paired tissues and descriptive ferredoxin 1 (FDX1)/dihydrolipoamide S-acetyltransferase (DLAT) immunohistochemistry provided preliminary tissue-level support. The final model comprised HAGLR, LINC00571, AC008915.2, and LINC01150. The signature separated high- and low-risk survival groups in the training and testing cohorts, with 1-, 3-, and 5-year area under the curve values of 0.675, 0.743, and 0.758, respectively. Risk groups also differed in immune-function scores, mutation and tumor mutational burden profiles, legacy TIDE scores, and predicted drug sensitivity. In 16 paired tissues, HAGLR and AC008915.2 were higher in tumor tissue, LINC00571 was higher in adjacent tissue, and LINC01150 was not significantly different. These findings provide internally validated prognostic and hypothesis-generating biological associations; external validation and functional cuproptosis experiments remain necessary before clinical or mechanistic conclusions.

Cite

APA

Zhao, F., Xu, J., Li, W., & Wang, Z. (2026). Construction of a Cuproptosis-Associated Long Noncoding RNA Prognostic Signature and Immune Profiling in Gastric Cancer. Journal of Visualized Experiments. https://doi.org/10.3791/71266

Vancouver

Zhao F, Xu J, Li W, Wang Z. Construction of a Cuproptosis-Associated Long Noncoding RNA Prognostic Signature and Immune Profiling in Gastric Cancer. Journal of Visualized Experiments. 2026. doi:10.3791/71266

BibTeX
@article{Zhao2026,
  author = {Zhao, Feng and Xu, Jialing and Li, Wei and Wang, Zhe},
  title = {Construction of a Cuproptosis-Associated Long Noncoding RNA Prognostic Signature and Immune Profiling in Gastric Cancer},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  number = {237},
  doi = {10.3791/71266}
}
Start for free →